Benitec Biopharma Limited (NASDAQ:BNTC) Stock Has Consensus Target Price of $22.00 According to Analysts

Shares of Benitec Biopharma Limited (NASDAQ:BNTC) have been given a consensus rating of “Moderate Buy” by the ten analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $22.00.

Several research firms have issued reports on BNTC. Wall Street Zen cut shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Wedbush raised their price target on Benitec Biopharma from $16.00 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a report on Thursday, October 15th. Raymond James Financial began coverage on Benitec Biopharma in a report on Friday, October 23rd. They issued an “outperform” rating and a $14.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating on shares of Benitec Biopharma in a report on Monday, November 2nd.

Institutional Trading of Benitec Biopharma

Several institutional investors and hedge funds have recently modified their holdings of BNTC. GAMMA Investing LLC grew its holdings in shares of Benitec Biopharma by 18.7% in the second quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 1,256 shares in the last quarter. Bank of America Corp DE increased its holdings in Benitec Biopharma by 43.3% during the 1st quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 5,251 shares during the period. ADAR1 Capital Management LLC bought a new stake in Benitec Biopharma during the 1st quarter valued at $186,000. Bank of New York Mellon Corp increased its stake in shares of Benitec Biopharma by 37.6% during the first quarter. Bank of New York Mellon Corp now owns 43,489 shares of the biotechnology company’s stock valued at $463,000 after buying an additional 11,877 shares during the period. Finally, AWM Investment Company Inc. bought a new stake in shares of Benitec Biopharma in the second quarter valued at about $2,515,000. 52.19% of the stock is currently owned by institutional investors.

Benitec Biopharma Stock Performance

BNTC stock opened at $9.87 on Thursday. Benitec Biopharma has a fifty-two week low of $7.89 and a fifty-two week high of $14.39. The company has a market capitalization of $344.36 million, a price-to-earnings ratio of -10.07 and a beta of 0.26. The business’s 50 day moving average price is $9.93 and its two-hundred day moving average price is $11.45.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Monday, September 14th. The biotechnology company reported ($0.26) EPS for the quarter, hitting analysts’ consensus estimates of ($0.26). Sell-side analysts forecast that Benitec Biopharma will post -1.35 earnings per share for the current year.

About Benitec Biopharma

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on its proprietary DNA-directed RNA interference (ddRNAi) technology. The platform is designed to enable cells to produce small hairpin RNA molecules that can selectively reduce the expression of disease-causing genes, potentially providing longer-lasting gene silencing than conventional RNA-based approaches.

The company’s lead program is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD1), a rare inherited disorder that affects muscles involved in swallowing and movement.